Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Outcome of Ixazomib (NINLARO®) Based Regimens in Chinese Patients With Multiple Myeloma Previously Receiving a Bortezomib/Carfilzomib-Based (re)Induction Regimen in Clinical Setting of Real World: An Open-Label, Single-Arm, Multicenter, Observation Study

NCT05013190 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT05013190
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05013190 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Outcome of Ixazomib (NINLARO®) Based Regimens in Chinese Patients With Multiple Myeloma Previously Receiving a Bortezomib/Carfilzomib-Based (re)Induction Regimen in Clinical Setting of Real World: An Open-Label, Single-Arm, Multicenter, Observation Study
Lead sponsor
Takeda
Phase
Observational
Overall status
Active, not recruiting
Start date
October 29, 2021
Completion date
December 31, 2026
Enrollment
72 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma